Benutzerspezifische Werkzeuge

Project-related list of own publications

  1. Därr R, Pamporaki C, Peitzsch M, Miehle K, Prejbisz A, Peczkowska M, Weismann D, Beuschlein F, Sinnott R, Bornstein SR, Neumann HP, Januszewicz A, Lenders J, Eisenhofer G. Biochemical diagnosis of phaeochromocytoma using plasma free normetanephrine, metanephrine and methoxytyramine: Importance of supine sampling under fasting conditions. Clin Endocrinol (Oxf). 2013 Sep 18. doi: 10.1111/cen.12327. [Epub ahead of print]
  2. Richter S, Qin N, Pacak K, Eisenhofer G. Role of hypoxia and HIF2α in development of the sympathoadrenal cell lineage and chromaffin cell tumours with distinct catecholamine phenotypic features. Adv Pharmacol. 2013;68:285-317. doi: 10.1016/B978-0-12-411512-5.00014-2.
  3. Eisenhofer G, Brown S, Peitzsch M, Pelzel D, Lattke P, Glöckner S, Stell A, Prejbisz A, Fassnacht M,  Beuschlein F, Januszewicz AJ, Siegert G, Reichmann H. Levodopa therapy in Parkinson’s disease: influence on liquid chromatographic tandem mass spectrometricbased measurements of plasma and urinary normetanephrine, metanephrine and methoxytyramine. Ann Clin Biochem. 2014 Jan;51(Pt 1):38-46. doi: 10.1177/0004563213487894. Epub 2013 Jul 19.
  4. Juratli TA, Peitzsch M, Geiger K, Schackert G, Eisenhofer G, Krex D. Accumulation of 2-hydroxyglutarate is not a biomarker for malignant progression in IDH-mutated low-grade gliomas. Neuro Oncol. 2013 Jun;15(6):682-90.
  5. Pamporaki C, Därr R, Bursztyn M, Glöckner S, Bornstein SR, Lenders JW, Pacak K, Krinner A, Eisenhofer G. Plasma-free vs deconjugated metanephrines for diagnosis of phaeochromocytoma. Clin Endocrinol (Oxf). 2013 Mar 5. doi: 10.1111/cen.12191. PMID: 23461656
  6. Peitzsch M, Pelzel D, Glöckner S, Prejbisz A, Fassnacht M, Beuschlein F, Januszewicz A, Siegert G, Eisenhofer G. Simultaneous liquid chromatography tandem mass spectrometric determination of urinary free metanephrines and catecholamines, with comparisons of free and deconjugated metabolites. Clin Chim Acta. 2013 Mar 15;418:50-8. doi: 10.1016/j.cca.2012.12.031. Epub 2013 Jan 9. PMID: 23313054
  7. Estey MP, Diamandis EP, Eisenhofer G, Pacak K, Maher ER, Young WF, de Krijger RR. Pheochromocytoma. Clin Chem. 2013 Mar;59(3):466-72. doi: 10.1373/clinchem.2012.182246. Epub 2012 Dec 3. PMID: 23209036
  8. Prejbisz, A., J.L. Lenders, G. Eisenhofer and A. Januszewicz. Mortality associated with phaeochromocytoma. Horm Metab Res. 2013 Feb;45(2):154-8. doi: 10.1055/s-0032-1331217. 
  9. Qin, N., M. Peitzsch, M. Menschikowski, G. Siegert, K. Pacak & G. Eisenhofer. Double stable isotope ultra performance liquid chromatographic tandem mass spectrometric quantification of tissue content and activity of phenylethanolamine N-methyltransferase, the crucial enzyme responsible for synthesis of epinephrine. Anal Bioanal Chem. 2013 Feb;405(5):1713-9. doi: 10.1007/s00216-012-6599-x.
  10. Vlenterie, M., U. Flucke, L.C. Hofbauer, H.J.L.M. Timmers, J. Gastmeier, D.E. Aust, W. van der Graaf, P. Wesseling, G. Eisenhofer and J.W.M. Lenders. Pheochromocytoma and gastrointestinal stromal tumors in patients with neurofibromatosis type I. Am J Med. 2013 Feb;126(2):174-80. doi: 10.1016/j.amjmed.2012.07.022.
  11. Eisenhofer, G., P. Lattke, M. Herberg, G. Siegert, N. Qin, R. Därr, J. Hoyer, A. Villringer, A. Prejbisz, A. Januszewicz, A. Remaley, V. Martucci, K. Pacak, H.A. Ross, F.C.G.J Sweep and J.W.M. Lenders. Reference intervals for plasma free metanephrines with an age adjustment for normetanephrine for optimised laboratory testing of phaeochromocytoma. Ann Clin Biochem. 2013 Jan;50(Pt 1):62-9. doi: 10.1258/acb.2012.012066.
  12. Därr R, Lenders JW, Stange K, Kindel B, Hofbauer LC, Bornstein SR, Eisenhofer G. Diagnosis of pheochromocytoma and paraganglioma: the clonidine suppression test in patients with borderline elevations of plasma free normetanephrine. Dtsch Med Wochenschr. 2013 Jan;138(3):76-81
  13. Gimenez-Roqueplo AP, Camumount-Prim A, Houzard C, Hignette C, Hernigou A, Halimi P, Niccoli P, Leboulleux S, Amar L, Borson-Chazot F, Cardot-Bauters C, Delemer B, Chabolle F, Coupier I, Libé R, Peitzsch M, Peyrard S, Tenenbaum F, Plouin PF, Chatellier G, Rohmer V. Imaging work-up for screening of paraganglioma and pheochromocytoma in SDHx mutation carriers - A multicenter prospective study from the PGL.EVA investigators. J Clin Endocrinol Metab. 2013 Jan;98(1):E162-73. doi: 10.1210/jc.2012-2975.
  14. Eisenhofer, G., J.W.M. Lenders, G. Siegert, S.R. Bornstein, P. Friberg, D. Milosevic, M. Mannelli, W.M. Linehan K. Adams, H.J. Timmers, and K. Pacak. Plasma methoxytyramine: A novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumor size, location and SDHB mutation status. European Journal of Cancer. 48: 1739-1749, 2012.
  15. Eisenhofer, G. and  J.W.M. Lenders. Rapid circulatory clearances and half-lives of plasma free metanephrines. Clinical Endocrinology. 77:484-485, 2012.
  16. Eisenhofer, G., A.S. Tischler and R.R. de Krijger. Diagnostic tests and biomarkers for pheochromocytoma and extra-adrenal paraganglioma: from routine laboratory methods to disease stratification. Endocrine Pathology. 23: 4-14, 2012.
  17. Eisenhofer, G. Screening for pheochromocytomas and paragangliomas. Current Hypertension Reports. 14:130-137, 2012.
  18. Mannelli, M., J.W. Lenders, K. Pacak, G. Parenti, and G. Eisenhofer. Subclinical phaeochromocytoma. Best Practice & Research Clinical Endocrinology & Metabolism. 26: 507-515, 2012.
  19. Eisenhofer, G., M. Schott, and S. Bornstein. Pheochromocytoma and paraganglioma: recent progress and new vistas for improved patient care. Hormone and Metabolic Research 44: 325-327, 2012.
  20. Därr, R., J.W.M. Lenders, L.C. Hofbauer, B. Naumann and G. Eisenhofer. Pheochromocytoma – update on disease management. Therapeutic Advances in Endocrinology and Metabolism 3: 11-26, 2012.
  21. Eisenhofer, G. C.D. Vocke, A. Elkahloun, T-T Huynh, T. Prodanov, J.W.M. Lenders, H.J. Timmers, J.N. Benhammou, W.M. Linehan and K. Pacak. Genetic screening for von Hippel-Lindau gene mutations in non-syndromic pheochromocytoma: low prevalence and false-positives or misdiagnosis indicates a need for caution. Hormone and Metabolic Research 44: 343-348, 2012.
  22. Burnichon, N., A. Cascón, F. Schiavi, N.P. Morales, I. Comino-Méndez, N. Abermil, L. Inglada-Pérez, A.A. de Cubas, L. Amar, M. Barontini, S. Bernaldo de Quirós, J. Bertherat, Y.-J. Bignon, M.J. Blok, S. Bobisse, S. Borrego, M. Castellano, P. Chanson, M.-D. Chiara, E.P.M. Corssmit, M. Giacchè, R.R. de Krijger, T. Ercolino, X. Girerd, E.B. Gómez-García, Á. Gómez-Graña, I. Guilhem, F.J. Hes, E. Honrado, E. Korpershoek, J.W.M. Lenders, R. Letón, A.R Mensenkamp, A. Merlo, L. Mori, A. Murat, P. Pierre, P.-F. Plouin, T. Prodanov, M. Quesada-Charneco, N. Qin, E. Rapizzi, V. Raymond, N. Reisch, G. Roncador, M. Ruiz-Ferrer, F. Schillo, A.P.A. Stegmann, C. Suarez, E. Taschin, H.J.L.M. Timmers, C.M.J. Tops, M. Urioste, F. Beuschlein, K. Pacak, M. Mannelli, P.L.M. Dahia, G. Opocher, G. Eisenhofer, A.-P. Gimenez-Roqueplo and M. Robledo. MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma. Clinical Cancer Research. 15: 2828-2837, 2012.
  23. Timmers, H.J.L.M., C.C. Chen, J.A. Carrasquillo, M. Whatley, A. Ling, G. Eisenhofer, K.S. King, J.U. Rao, K.T. Adams and K. Pacak. Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-FDG PET. Journal of the National Cancer Institute. 104: 700-708, 2012.
  24. Martiniova, L., S. Cleary, E.W. Lai, D.O. Kiesewetter, J. Seidel, L. Dawson, J. Phillips, D. Thomasson, X. Chen, G. Eisenhofer, J. Powers, R. Kvetnansky and K. Pacak. Usefulness of [18F]-DA and [18F]-DOPA for PET imaging in a mouse model of pheochromocytoma. Nuclear Medicine and Biology. 39: 215-26, 2012.
  25. Willenberg, H.S., M. Gruber, G. Eisenhofer and S.R. Bornstein. Endocrine hypertension: new aspects and developments. Deutsche Medizinische Wochenschrift 37: 627-630, 2012.
  26. Peitzsch M, Prejbisz A, Kroiß M, Beuschlein F, Arlt W, Januszewicz A, Siegert G, Eisenhofer G. Analysis of plasma 3-methoxytyramine, normetanephrine and metanephrine by ultraperformance liquid chromatography-tandem mass spectrometry: utility for diagnosis of dopamine-producing metastatic phaeochromocytoma. Ann Clin Biochem. 2013 Mar;50(Pt 2):147-55. doi: 10.1258/acb.2012.012112. PMID: 23512172
  27. Därr R, Lenders JW, Stange K, Kindel B, Hofbauer LC, Bornstein SR, Eisenhofer G. [Diagnosis of pheochromocytoma and paraganglioma: the clonidine suppression test in patients with borderline elevations of plasma free normetanephrine]. Dtsch Med Wochenschr. 2013 Jan;138(3):76-81. doi: 10.1055/s-0032-1327395. Epub 2013 Jan 8. German. PMID: 23299341 [PubMed - indexed for MEDLINE]
  28. Eisenhofer G, Timmers HJ, Lenders JW, Bornstein SR, Tiebel O, Mannelli M, King KS, Vocke C, Linehan WM, Bratslavsky G, Pacak K. Age at diagnosis of pheochromocytoma differs according to catecholamine phenotype and tumor location. J Clin Endocrinol Metab 2011 Feb;96(2):375-84.
  29. Eisenhofer G, Lenders JW, Timmers HJ, Mannelli M, Grebe SK, Hofbauer LC, Bornstein SR, Tiebel O, Adams K, Bratslavsky G, Linehan WM, Pacak K. Measurements of Plasma Methoxytyramine, Normetanephrine and Metanephrine as Discriminators of Different Hereditary forms of Pheochromocytoma. Clin Chem. 2011 Mar;57(3):411-20.
  30. Eisenhofer, G., H.J. Timmers, J.W.M. Lenders, S.R. Bornstein, O. Tiebel, M. Mannelli, K.S. King, C. Vocke, W.M. Linehan, G. Bratslavsky and K. Pacak. Age at diagnosis of pheochromocytoma differs according to catecholamine phenotype and tumor location. Journal of Clinical Endocrinology and Metabolism. 96: 375-384, 2011.
  31. Eisenhofer, G., J.W.M. Lenders, H.J. Timmers, M. Mannelli, L.C. Hofbauer, S.R. Bornstein, O. Tiebel, K. Adams, G. Bratslavsky, W.M. Linehan and K. Pacak. Measurements of plasma methoxytyramine, normetanephrine and metanephrine as discriminators of different hereditary forms of pheochromocytoma. Clinical Chemistry 57:411-420, 2011.
  32. Därr, R., G. Eisenhofer, J. Kotzerke, K. Zöphel, C. Stroszczynski, J. Deinum, L.J Schultze Kool, S. Pistorius, H. Neumann, S.R. Bornstein and L.C. Hofbauer. Is there still a place for adrenal venous sampling in the diagnostic localization of pheochromocytoma? Endocrine. 40: 75-79, 2011.
  33. Prejbisz, A., J.W. Lenders, G. Eisenhofer and A. Januszewicz. Cardiovascular manifestations of phaeochromocytoma. Journal of Hypertension 29: 2049-60, 2011.
    King, K.S., T. Prodanov, V. Kantorovich, T. Fojo, J.K. Hewitt, M. Zacharin, R. Wesley, M. Lodish, M. Raygada, A.-P. Gimenez-Roqueplo, S. McCormack, G. Eisenhofer, D. Milosevic, E. Kebebew, C.A. Stratakis and K. Pacak. Metastatic pheochromocytoma/paraganglioma related to primary tumor development in childhood or adolescence: significant link to SDHB mutations. Journal of Clinical Oncology 29: 4137-42, 2011.
  34. Singer, J., C.A. Koch, W. Kassahun, P. Lamesch, G. Eisenhofer, R. Kluge, T. Lincke, M. Seiwerts, G. Borte, K. Schierle and R. Paschke. A patient with a large recurrent pheochromocytoma demonstrating the pitfalls of diagnosis. Nature Reviews Endocrinology. 7:749-55, 2011.
  35. Papewalis, C., C. Kouatchoua, M. Ehlers, B. Jacobs, D. Porwol, S. Schinner, H.S. Willenberg, M. Anlauf, A. Raffel, G. Eisenhofer, H.P. Neumann, S.R. Bornstein, W.A. Scherbaum, and M. Schott. Chromogranin A as a potential target for immunotherapy of malignant pheochromocytoma. Molecular and Cellular Endocrinology. 335: 69-77, 2011.